Mary Woolley

Dear Research Advocate:

Dear Research Advocate:

Dear Research Advocate:

The Bureau of Economic Analysis has reclassified research and development costs from an “expense” to an “investment” when calculating GDP. We think Members of Congress should do the same. Common sense tells us R&D is an investment, not an expense; in general conversation we all talk about R&D as an investment, but it isn’€™t accounted for that way on the federal books. The arguments we’€™ve been making are now further bolstered by the BEA’€™s decision. Spread the word!

LOW PERCENTAGE HEAR ABOUT CLINICAL TRIALS FROM HEALTH CARE PROVIDERS

Dear Research Advocate:

Dear Research Advocate:

by Mary Woolley, Research!America President and CEO. This entry was originally posted as a guest contribution to PhRMA’€™s Conversations forum.

Dear Research Advocate:

Dear Research Advocate:

Dear Research Advocate:

Pages

Subscribe to RSS - Mary Woolley